---
title: 'Director, Commercial Project Management & Launch Excellence at Remix Therapeutics'
canonical: 'https://feeny.ai/job/director-commercial-project-management-launch-excellence-remix-therapeutics-r7bj18tryxga'
type: 'job'
last_seen: '2026-11-07'
---

# Director, Commercial Project Management & Launch Excellence at Remix Therapeutics

- **Company:** Remix Therapeutics
- **Location:** Watertown, MA
- **Posted:** 2026-10-26
- **Last confirmed live:** 2026-11-07
- **Apply:** https://job-boards.greenhouse.io/remixtherapeutics/jobs/4747673005

## Job description

Remix Therapeutics is a clinical-stage biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin. Remix's REMaster™ technology platform leverages data science, biomolecular sciences and chemistry approaches to identify orally administered compounds that modulate gene expression. Remix's therapeutic approach led to the discovery of REM-422, an investigational small molecule designed to modulate RNA processing in oncology, currently being evaluated in two clinical programs, 1) the ARIA clinical study, a Phase 1/2 clinical study in adenoid cystic carcinoma (ACC), and 2) a Phase 1 clinical study in acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS).

In June 2026, Remix announced an agreement to merge with Passage Bio, with the combined company expected to operate as Remix Therapeutics and trade on Nasdaq. The announced transaction included a concurrent $100 million private placement intended to support continued development of its pipeline. Remix remains focused on translating its RNA-processing science into meaningful treatment options for patients with significant unmet medical needs.

Position Summary:

The Director will translate commercial strategy into an actionable enterprise launch plan, align stakeholders around priorities, and drive accountability for delivery. Working closely with Commercial, Medical Affairs, Clinical Development, Regulatory, Market Access, Technical Operations, Quality, Finance, Legal and Compliance, IT, and Human Resources, this individual will connect workstreams, surface risks, and help leadership make timely decisions.

This is a hands-on role for a leader who can build practical processes, influence without direct authority, and move comfortably between strategic planning and detailed execution. The Director owns integrated launch management, working with functional leaders who remain accountable for their strategies and deliverables.

This is an opportunity to help lead the integrated planning, coordination, execution, and tracking of the potential launch of REM-422, subject to regulatory approval.

Key Responsibilities:

- Build and maintain the integrated launch roadmap, defining workstreams, deliverables, accountable owners, milestones, interdependencies, and the critical path from prelaunch preparation through early commercialization.
- Partner with leaders to translate launch objectives into functional plans, readiness criteria, resource requirements, and measurable outcomes. Reconcile competing priorities and identify gaps between functional plans.
- Establish fit-for-purpose launch governance, cross-functional launch team, workstream meetings, decision rights, and escalation pathways.
- Lead focused meetings with clear agendas, decisions, owners, and follow-up actions. Maintain a decision log and ensure unresolved issues reach the appropriate decision-maker.
- Provide concise leadership updates on readiness, critical dependencies, and decisions required. Present options and tradeoffs with a recommended path forward.
- Build productive relationships across internal teams and external partners. Clarify expectations, resolve handoff gaps, and address capacity constraints before they affect launch readiness.
- Implement practical project management standards, templates, dashboards, and a shared source of launch information. Keep processes proportional to the size and needs of the organization.
- Maintain an integrated register of risks, assumptions, issues, and dependencies. Assign owners, evaluate potential impact, and track mitigation plans, contingency actions, and escalation triggers.
- Assist in readiness reviews and launch simulations to test critical workflows, such as the path from prescription through coverage, dispensing, and patient support. Confirm evidence of readiness and close identified gaps.

Qualifications:

- Bachelor’s degree in life sciences, business, or a related discipline, or equivalent relevant experience.
- 10 or more years of relevant experience in biotechnology or pharmaceuticals, including substantial responsibility for commercial project management, launch readiness, or cross-functional program leadership.
- Launch expertise: Understand the sequence and dependencies of commercialization, including regulatory milestones, medical readiness, market access, patient services, field execution, distribution, supply, and commercial systems.
- Project management discipline: Apply integrated scheduling, critical path analysis, capacity planning, change control, scenario planning, and risk management. Use tools such as Smartsheet, Microsoft Project, or comparable platforms to support execution.
- Influence and facilitation: Align senior stakeholders and functional experts without direct authority, resolve disagreements constructively, and secure clear commitments across competing priorities.
- Demonstrated leadership of at least one product launch from prelaunch planning through commercialization, with direct responsibility for an integrated launch plan and governance. Experience with a company’s first commercial launch is strongly preferred.
- Experience in a small or emerging biotechnology company, including building capabilities with lean teams, limited infrastructure, and external service providers. Experience with oncology and/or rare disease therapies is preferred.

Salary Range:

$206,000 - $252,000 USD

This range reflects the expected base salary for this position, plus bonus, equity, and benefits as applicable.  Actual salaries may vary based on factors, such as skill, experience, and qualification for the role.

## About Remix Therapeutics

## Company Overview
- **One-liner**: Clinical-stage biotechnology company developing first-in-class oral small molecule therapies that reprogram RNA processing to address previously undruggable drivers of cancer and other diseases.
- **Entity Type**: Private (Venture-backed; merged with Passage Bio in June 2026 with a concurrent $100M private placement)
- **Headquarters**: Watertown, Massachusetts, United States
- **Founded**: 2018
- **Founders**: Peter Smith, PhD

## Core Business
- **Primary industry**: Biotechnology – RNA-targeted therapeutics, oncology
- **Target customers**: B2B (pharmaceutical partners like Roche and Johnson & Johnson) and B2C (patients with high-unmet-need cancers, served through healthcare providers)
- **Mission or purpose statement**: “Reprogramming RNA to transform patients’ lives” – focused on modulating RNA processing to address disease drivers at their origin

## Products & Services
- **REM‑422**: First-in-class, orally available small molecule mRNA degrader targeting the historically undruggable transcription factor MYB. Currently in Phase 1 clinical trials for acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (HR‑MDS), and adenoid cystic carcinoma (ACC). Granted FDA Fast Track designation for ACC.
- **REMaster™ Drug Discovery Platform**: Proprietary platform that designs small molecules to harness cellular RNA‑processing machinery, enabling modulation of gene expression for targets previously considered intractable. Used for internal pipeline and partnered programs.

## Market Standing
- **Valuation/Market Cap**: Not publicly disclosed (private company; post-merger valuation unknown)
- **Key Metric**: Total funding ~$240.7M (including a $100M private placement concurrent with the Passage Bio merger in June 2026). Annual revenue (2025 estimate): $3.2M (typical for a clinical‑stage biotech).
- **Notable Investors/Partners**:  
  - Investors: Surveyor Capital (Series B lead, $70M), Foresite Capital (Series A lead, $65M), The Column Group (Venture Round lead, $60M)  
  - Partners: Roche (collaboration for RNA‑processing modulators), Johnson & Johnson Innovative Medicine (multi‑year, three‑target oncology/immunology collaboration)  
- **Growth Signals**:  
  - Preliminary Phase 1 data for REM‑422 showed strong anti‑tumor activity and favorable safety in ACC  
  - FDA Fast Track designation for REM‑422 in ACC  
  - Merger with Passage Bio (June 2026) brings additional capital and pipeline synergies  
  - Active job postings up 200% month‑over‑month and quarter‑over‑quarter  
  - Headcount of 49 employees with a heavy concentration in research (43%)

## Competitive Advantages
- **Proprietary REMaster platform** uniquely enables oral small‑molecule modulation of RNA processing, expanding the druggable target space beyond traditional protein inhibition
- **First‑in‑class oral MYB mRNA degrader** (REM‑422) addresses a transcription factor long considered undruggable
- **Top‑tier pharma collaborations** with Roche and J&J validate the technology and provide non‑dilutive funding
- **Strong scientific leadership** (CEO/co‑founder Peter Smith, PhD, formerly CSO at H3 Biomedicine, where he advanced three molecules to the clinic)

## Strategic Focus
- Advance REM‑422 through Phase 1 trials across multiple MYB‑driven cancers (AML, HR‑MDS, ACC) and expand into additional solid tumors
- Leverage the REMaster platform to discover new RNA‑processing modulators for oncology and immunology
- Deepen existing pharma partnerships and seek new collaborations to accelerate pipeline growth
- Integrate the recently merged Passage Bio assets and utilize the $100M private placement to fund clinical development

## Why Work Here
- **Culture**: Values-driven environment centered on “True to Our RNA” (scientific integrity), “Courageous Curiosity” (bold innovation), and “Remixing Together” (collaboration and mutual support). Employees describe a flat, science‑first culture where diverse perspectives are welcomed.
- **Work model**: Hybrid? While not explicitly stated, the company has three offices in the Boston area (Watertown HQ, One Kendall Square Cambridge, and another Cambridge location). Lab‑based roles are likely on‑site; corporate roles may offer flexibility.
- **Perks & environment**: Small company (~49 people) with the energy of a startup but backed by significant funding and pharma partnerships. Employees share a strong sense of mission to bring new therapies to patients with few options. “We take our work seriously but not ourselves.”
- **Growth opportunity**: Rapidly advancing clinical pipeline and post‑merger expansion offer career advancement in a high‑visibility biotech. Recent ramp‑up in hiring (3 active postings for senior leadership roles like VP of Program Team Lead, VP of Biostatistics, and Senior Manager of Strategy & BD) signals scaling.

## Sources
1. [Remix Therapeutics Home](https://www.remixtx.com/)
2. [Remix Therapeutics About Us](https://www.remixtx.com/about/)
3. [Remix Therapeutics Join Us](https://www.remixtx.com/join/)
4. [Remix Therapeutics LinkedIn](https://www.linkedin.com/company/remix-therapeutics)
5. [Remix Therapeutics Greenhouse Careers](https://job-boards.greenhouse.io/remixtherapeutics)

## Other roles at Remix Therapeutics

- [Director, Clinical Pharmacology](https://feeny.ai/job/director-clinical-pharmacology-remix-therapeutics-watertown-0wtvv2v3477g) — Watertown, MA
- [Senior Director, GCP Quality](https://feeny.ai/job/senior-director-gcp-quality-remix-therapeutics-watertown-ancn66bxrnf3) — Watertown, MA
- [Associate Director, Clinical Data Management](https://feeny.ai/job/associate-director-clinical-data-management-remix-therapeutics-watertown-qq070g410ywh) — Watertown, MA
- [Head of Medical Affairs](https://feeny.ai/job/head-of-medical-affairs-remix-therapeutics-watertown-x0b0ddpp9nnc) — Watertown, MA
- [Vice President/Senior Director, Nonclinical Drug Safety & Toxicology](https://feeny.ai/job/vice-president-senior-director-nonclinical-drug-safety-toxicology-remix-hcv58wta0q0b) — Watertown, MA
- [Vice President, Clinical Development](https://feeny.ai/job/vice-president-clinical-development-remix-therapeutics-watertown-0ewyfa0bvx9g) — Watertown, MA